Market Cap | 180.53M | P/E | - | EPS this Y | 23.00% | Ern Qtrly Grth | - |
Income | -131.39M | Forward P/E | -1.43 | EPS next Y | -4.50% | 50D Avg Chg | -4.00% |
Sales | 2.04M | PEG | 0.05 | EPS past 5Y | - | 200D Avg Chg | -42.00% |
Dividend | N/A | Price/Book | 0.65 | EPS next 5Y | -16.20% | 52W High Chg | -78.00% |
Recommedations | 1.70 | Quick Ratio | 10.34 | Shares Outstanding | 84.72M | 52W Low Chg | 8.00% |
Insider Own | 28.14% | ROA | -19.24% | Shares Float | 33.52M | Beta | 1.37 |
Inst Own | 58.78% | ROE | -55.95% | Shares Shorted/Prior | 3.28M/2.23M | Price | 3.03 |
Gross Margin | - | Profit Margin | - | Avg. Volume | 95,916 | Target Price | 10.20 |
Oper. Margin | -4,507.78% | Earnings Date | - | Volume | 56,178 | Change | 0.33% |
Century Therapeutics, Inc., a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma. The company is also involved in the development of CNTY-102, a bi-specific CD19 + CD22 CAR-iT product candidate for relapsed, refractory B-cell lymphoma and other B-cell malignancies; and CNTY-107, a Nectin-4 CAR-iT targeted product candidate for Nectin-4 positive solid tumors. In addition, it has a strategic collaboration with Bristol-Myers Squibb Company to develop and commercialize up to four iNK or iT programs, including CNTY-104, a multi-specific collaboration program targeting acute myeloid leukemia; and CNTY-106, a multi-specific collaboration program for multiple myeloma. The company was incorporated in 2018 and is headquartered in Philadelphia, Pennsylvania.
HC Wainwright & Co. | Buy | Aug 15, 24 |
Piper Sandler | Overweight | Jun 17, 24 |
HC Wainwright & Co. | Buy | Jun 4, 24 |
HC Wainwright & Co. | Buy | May 10, 24 |
Piper Sandler | Overweight | Apr 12, 24 |
Canaccord Genuity | Buy | Mar 15, 24 |
HC Wainwright & Co. | Buy | Mar 15, 24 |
HC Wainwright & Co. | Buy | Dec 7, 23 |
JP Morgan | Neutral | Aug 28, 23 |
Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
---|---|---|---|---|---|---|---|---|
Borges Luis | Chief Scientific Off.. Chief Scientific Officer | Mar 21 | Sell | 3.68 | 144,911 | 533,272 | 249,083 | 03/23/23 |
Borges Luis | Chief Scientific Off.. Chief Scientific Officer | Mar 21 | Option | 1.03 | 350,244 | 360,751 | 264,680 | 03/23/23 |
Versant Venture Capital VI, L.... | 10% Owner 10% Owner | Aug 09 | Sell | 13.03 | 550,000 | 7,166,500 | 11,816,814 | 08/11/22 |